Sponsored by:
Hewlett Packard (HPQ)
Dell (DELL)
Facebook (FB)
Apple (AAPL)
Focus Stocks
Featured Stories
Fred's First Quarter 2012 EPS Increase 17%
Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook
Best ETFs For Facebook Exposure
McDonald's Announces Quarterly Cash Dividend
Intuitive Surgical Bullish Signs
Early Research Calls ( VRX, PGR, STJ, HES, TRMK, GD, RBS, GOLD, RYAAY, WLP )
Published on Thursday, 26 January 2012 08:25 Written by Christopher Lynn
New York, January 26th (TradersHuddle.com) - The following are top upgrades and downgrades before the market opens.
Valeant Pharmaceuticals International (NYSE:VRX) was downgraded to a Neutral from Overweight at Piper Jaffray.
Progressive (NYSE:PGR) was downgraded to a Sell from Neutral at Goldman Sachs.
St. Jude Medical (NYSE:STJ) was upgraded to a Buy from Hold at Canaccord Genuity.
Hess Corporation (NYSE:HES) was downgraded to a Hold from Buy at Deutsche Bank.
Trustmark (NASDAQ:TRMK) was downgraded to Underperform from Market Perform at Keefe Bruyette.
General Dynamics (NYSE:GD) was downgraded to Perform from Outperform at Oppenheimer on valuation.
Royal Bank of Scotland (NYSE:RBS) was downgraded to Add from Buy at WestLB.
Randgold Resources (NASDAQ:GOLD) was downgraded to a Neutral from Overweight at JPMorgan.
Ryanair Holdings plc (NASDAQ:RYAAY) was downgraded to a Neutral from Buy at Nomura.
WellPoint (NYSE:WLP) was downgraded to a Hold from Buy at Jefferies.
Related Articles
- Gentium Reports First Quarter Financial Results
- Critical Alerts For Research in Motion, Hess, Lions Gate, TRW Automotive, and Arena Pharmaceuticals Released By InvestorsObserver
- Progressive Reports April Results
- Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR
- Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
- Hess @ Year Lows
- FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings
- St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension
- Upgrades & Downgrades
- Trustmark Corporation’s CEO to Address the Gulf South Bank Conference
Related Partner Headlines
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal for C$28M - Benzinga
- St Jude Medical Inc. (STJ): Today's Featured Health Services Loser - TheStreet.com
- Hess Stock Hits New 52-Week Low (HES) - TheStreet.com
- Morgan Stanley Remains Underweight After Worst April EPS for Progressive in 10+ Years - Benzinga
- FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings - Benzinga
- Hess Corp Stock Downgraded (HES) - TheStreet.com
- UPDATE: Citigroup Reiterates Sell Rating, Lowers PT for St. Jude Medical - Benzinga
- UPDATE: Goldman Sachs Upgrades St. Jude Medical; Raises PT - Benzinga
- Waiting to Wade Into Oil - TheStreet.com
- St. Jude Medical Announces Results of SCD-HeFT 10-Year Follow-up Study; Confirms ICD Therapy Improves Long-Term Survival of Patients with Heart Failure - Benzinga
Volatile market? That's when profit potential skyrockets for options traders. Now you can get up to 50 trade opportunities a week from top options experts -- plus much more -- on our exciting new site OptionsProfits.
Try it FREE!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
